Loading...
  • Patients
  • The optimal dosing regimen for use of indinavir in pregnant patients has not been established. (nih.gov)
  • 2,3 Use of unboosted indinavir is not recommended in pregnant patients with HIV because of the substantially lower antepartum exposures observed in these studies and the limited experience in this patient population. (nih.gov)
  • 5 In a small study of 2 patients who received indinavir 800 mg and ritonavir 200 mg twice daily, third-trimester indinavir area under the curve exceeded that for historical non-pregnant controls. (nih.gov)
  • All patients who wish to remain in this study after 96 weeks of therapy and who do not meet off study criteria will be permitted to receive extended treatment with their current indinavir combination therapy for an additional 48 weeks. (clinicaltrials.gov)
  • doses
  • Indinavir was administered to Rhesus monkeys during the third trimester (at doses up to 160 mg/kg twice daily) and to neonatal Rhesus monkeys (at doses up to 160 mg/kg twice daily). (nih.gov)
  • Treatment
  • There has been no evidence of teratogenicity or treatment-related effects on embryonic/fetal survival or fetal weights of indinavir in rats, rabbits, or dogs at exposures comparable to, or slightly greater than, therapeutic human exposure. (nih.gov)
  • maternal
  • Indinavir is excreted in the milk of lactating rats at concentrations slightly greater than maternal levels. (nih.gov)